B. Yа. Alekseev
- Pulmonary and Respiratory Medicine top 0.2%
- Cancer Research top 0.5%
- Oncology top 1%
- Molecular Biology top 5%
- Radiology, Nuclear Medicine and Imaging top 1%
- Co-authors
- Karim FizaziNobuaki MatsubaraKim N.Mustafa ÖzgüroğluLuis FeinSusan FeyerabendAndrew ProtheroeA. Rodrı́guez-Antolı́n
- Topics
- Prostate Cancer Treatment and Research (117 papers)Renal cell carcinoma treatment (77 papers)Bladder and Urothelial Cancer Treatments (51 papers)
- Partner nations
- RussiaUnited StatesSpain
In The Last Decade
B. Yа. Alekseev
243 papers receiving 7.5k citations
Hit Papers
Peers
Comparison fields: 5 of 135
- Pulmonary and Respiratory Medicine 5.4k
- Cancer Research 2.3k
- Oncology 2.2k
- Molecular Biology 2.2k
- Radiology, Nuclear Medicine and Imaging 1.5k
Countries citing papers authored by B. Yа. Alekseev
This map shows the geographic impact of B. Yа. Alekseev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Yа. Alekseev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Yа. Alekseev more than expected).
Fields of papers citing papers by B. Yа. Alekseev
This network shows the impact of papers produced by B. Yа. Alekseev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Yа. Alekseev. The network helps show where B. Yа. Alekseev may publish in the future.
Co-authorship network of co-authors of B. Yа. Alekseev
This figure shows the co-authorship network connecting the top 25 collaborators of B. Yа. Alekseev. A scholar is included among the top collaborators of B. Yа. Alekseev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Yа. Alekseev. B. Yа. Alekseev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 14 | |
| 4 | 0 | |
| 5 | Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinomabreakdown → | 183 |
| 6 | 4 | |
| 7 | 0 | |
| 8 | 1 | |
| 9 | 0 | |
| 10 | 2 | |
| 11 | BCD-100 - first russian PD-1 inhibitor | 3 |
| 12 | MAIN MOLECULAR TARGETS FOR PROSTATE CANCER THERAPY | 0 |
| 13 | 0 | |
| 14 | 2 | |
| 15 | 1 | |
| 16 | 1 | |
| 17 | 1 | |
| 18 | 2 | |
| 19 | 1 | |
| 20 | Intraoperative photodynamic therapy of bladder cancer with alasens (results of multicenter trial) | 1 |
About B. Yа. Alekseev
B. Yа. Alekseev is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology, having authored 316 papers that have together received 7.7k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (117 papers), Renal cell carcinoma treatment (77 papers) and Bladder and Urothelial Cancer Treatments (51 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (5.4k citations), Cancer Research (2.3k citations) and Oncology (2.2k citations). B. Yа. Alekseev has collaborated with scholars based in Russia, United States and Spain. Frequent co-authors include Karim Fizazi, Nobuaki Matsubara, Kim N., Mustafa Özgüroğlu, Luis Fein, Susan Feyerabend, Andrew Protheroe, A. Rodrı́guez-Antolı́n, Dingwei Ye and Neal D. Shore. Their work appears in journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.